Amazon Business has hit pause on its plan to sell and distribute pharmaceutical products to hospitals after investigating the possibility last year.
Amazon Business has hit pause on its plan to sell and distribute pharmaceutical products to hospitals after investigating the possibility last year. The company says it is instead focusing on selling less sensitive medical supplies to hospitals and smaller clinics, though it has found this business to be more challenging than anticipated.
The change in plans comes in part because of the struggle that Amazon has had in trying to convince hospitals to change their traditional purchasing process, which typically involves a sophisticated logistics network that can handle temperature-sensitive pharmaceutical products. Many hospitals also own a stake in group purchasing networks that negotiate on the hospital’s behalf. Amazon’s current logistics network doesn’t offer this type of technology, and a supply chain would be costly for Amazon to build.
“The hospital and healthcare systems have entangling alliances with their existing purchasing and supply chain partners. It’s very difficult to replicate the Amazon buying experience in healthcare,” Tom Cassels, head of strategy and business development at Leidos Health, told CNBC.
Additionally, Amazon is not currently selling products that are classified as high-risk devices, such as pacemakers, that hospitals may need. Instead, for the past several years, Amazon has focused on selling less-risky products, like glucometers, gloves, and stethoscopes for medical clinics.
Amazon, however, remains hopeful about its foray into healthcare. A spokesperson for the online retailer told CNBC, “Amazon Business serves healthcare customers of all sizes, from large [integrated delivery networks], to small-and-medium sized community hospitals. We also serve customers from physician and dental offices to senior living and long-term care facilities.”
For now, it seems that the niche for Amazon Business in the healthcare sphere remains in smaller practices, such as dental offices, free-standing ambulatory surgery centers, and small physician practices where providers appreciate the affordability and convenience of its service.
When Amazon originally announced the potential for entering the medical supply and pharmaceutical space, several healthcare and pharmaceutical distribution companies saw their stocks take a hit in response. However, since the recent shift in plans, shares of pharmacies and drug distributors including Cardinal Health, CVS, and Walgreens have spiked.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.